Abstract: Pancreatic cancer is considered as one of the most aggressive malignancies with poor prognosis. Only a few newly diagnosed patients are possible candidates for curative resection. With the development of medical technology， there is a new subtype of pancreatic cancer called borderline resectable pancreatic cancer （BRPC） that has been distinguished from resectable and unresectable cases. BRPC has low R0 resection rate and high risk of recurrence. Neoadjuvant therapy is playing an important role in BRPC aiming to improve the R0 resection rate and prolong survival. How to optimize neoadjuvant therapy strategy and improve prognosis of BRPC is worth of attention.